about
Recent developments in treatment of latent tuberculosis infectionTuberculosis control: challenges of an ancient and ongoing epidemicDiagnosis and treatment of latent infection with Mycobacterium tuberculosisHepatotoxicity from antituberculous therapy in the elderly: a systematic reviewIncidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisIsoniazid-related fatal hepatitis.Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patientsFatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.A review of isoniazid-related hepatotoxicity during chemoprophylaxis.Intuitive weights of harm for therapeutic decision making in smear-negative pulmonary Tuberculosis: an interview study of physicians in India, Pakistan and Bangladesh.Hepatic reactions to drugs.Adverse reactions to first-line antituberculosis drugs.Adverse events associated with treatment of latent tuberculosis in the general population.Isoniazid liver injury during chemoprophylaxis in childrenAntituberculosis drug-induced hepatotoxicity in childrenClose contact investigation of TB in high-burden, low- and middle-income countries.Re-examining treatment of latent tuberculosis infectionUnder-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.Antituberculosis drugs and hepatotoxicity.Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature.Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.A guide to the management of tuberculosis in patients with chronic liver disease.Treatment of latent tuberculosis infection: An update.Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration.GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury.The role of metabolism in the hepatotoxicity of isoniazid and iproniazid.Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation.PharmGKB summary: isoniazid pathway, pharmacokinetics.Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation.Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.Isoniazid for latent tuberculosis infection: approaching 40 and reaching its prime.Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis?
P2860
Q24630473-B61F3550-1C1C-40C1-B3E2-9C34B671F868Q26206908-8B97FB1A-6B5B-4014-B6E0-03778FB1561FQ27021614-694DE235-5273-4988-A2F4-144C5F105F01Q27022370-63144705-6A29-41FD-B953-A95DAED69EA9Q28207601-ECC7150B-9972-4BC7-AFBC-EE453FB2DF40Q28379062-CEA5544D-EE5C-4B82-84F1-337A6EECF108Q28542785-99D13750-DA16-4556-AF2F-2936BC0C95A3Q33607506-B1B092CD-7657-452E-8739-65A420AF6772Q33951250-DB2806C2-DBFB-4197-9155-AD468CADAEDDQ34021616-996E8594-DDB1-46C7-9F49-3B08D61348AFQ34475653-D0CB47D4-C933-4275-8235-D0AB350C2A4FQ34497890-157E25A4-7AC3-4CB8-BC86-2AB15D667A32Q34589993-E8892840-D9BA-4135-94C5-206BC35FB910Q34986936-23925F69-7588-430E-8672-A8B1F821BA6CQ35096954-24CB08C1-E383-4F43-897B-EB254823FD4EQ35443130-6DCBC524-DF5F-4F43-A05C-34E9117C703EQ36170382-41A80C19-1B5E-46B4-9C9F-BBC67F0180E2Q36299913-F8211D6A-0E31-4CBF-843B-47B134462FC1Q36628708-977AD553-909A-436A-A911-5954C3674943Q37211281-D168F799-F654-4AB7-B434-7CBE69950AE8Q37239604-42762178-DE68-4CAB-BACB-F72666F6CF8CQ37336390-8FD6FB92-8FAC-4525-866D-55C13251468EQ37613934-713F9315-8295-4437-9DA1-5C26A00FED96Q37735306-2D181333-63E6-4629-9F1A-303B56524A24Q38037032-2324892C-E774-4845-9AD6-78557CA2FAF0Q38078780-22473103-78C1-4A5F-AA7C-1E2A7832FBAEQ38208324-57FF075E-941D-484A-85F7-4AAC37BAC2DCQ38651282-B3034A0D-635C-4E1F-956A-B88BE2CCC255Q39850167-C5839066-2B45-4B63-BD3A-A3A4B77B4962Q40631991-AA27979A-7F12-428B-9BB4-DC78308C9B7FQ42090708-CF7B1B8E-F85D-4335-9A7C-F8A8C5EF3213Q42873894-6AF7CB41-A415-42C4-A1A2-90930198822BQ43611407-B5477C86-8C8E-4E6F-B09B-86760B018BDEQ44545435-F9B302BE-8632-48AB-9C57-50E87BC0BB27Q46741889-CEEB33E1-CE2F-4056-99F0-74E58FF970E2
P2860
description
1972 nî lūn-bûn
@nan
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
1972年论文
@zh
1972年论文
@zh-cn
name
Isoniazid-associated hepatitis. Report of an outbreak.
@en
Isoniazid-associated hepatitis. Report of an outbreak.
@nl
type
label
Isoniazid-associated hepatitis. Report of an outbreak.
@en
Isoniazid-associated hepatitis. Report of an outbreak.
@nl
prefLabel
Isoniazid-associated hepatitis. Report of an outbreak.
@en
Isoniazid-associated hepatitis. Report of an outbreak.
@nl
P2093
P1476
Isoniazid-associated hepatitis. Report of an outbreak.
@en
P2093
R A Garibaldi
R E Drusin
S H Ferebee
P304
P356
10.1164/ARRD.1972.106.3.357
P577
1972-09-01T00:00:00Z